Identifying Key Drivers of Efficient B Cell Responses: On the Role of T Help, Antigen-Organization, and Toll-like Receptor Stimulation for Generating a Neutralizing Anti-Dengue Virus Response
Authors:
- Jan M. SobczakJSJan M. Sobczak
- Irena BarkovskaIBIrena Barkovska
- Ina BalkeIBIna Balke
- Dominik A. RothenDRDominik A. Rothen
- Mona O. MohsenMMMona O. Mohsen
- Dace SkrastinaDSDace Skrastina
- Anete OgrinaAOAnete Ogrina
- Byron MartinaBMByron Martina
- Juris JansonsJuris Jansons
- Janis BogansJBJanis Bogans
- Monique VogelMonique Vogel
- Martin F. BachmannMartin F. Bachmann
Open Access
Abstract
T help (Th), stimulation of toll-like receptors (pathogen-associated molecular patterns, PAMPs), and antigen organization and repetitiveness (pathogen-associated structural patterns, PASPs) were shown numerous times to be important in driving B-cell and antibody responses. In this study, we dissected the individual contributions of these parameters using newly developed “Immune-tag” technology. As model antigens, we used eGFP and the third domain of the dengue virus 1 envelope protein (DV1 EDIII), the major target of virus-neutralizing antibodies. The respective proteins were expressed alone or genetically fused to the N-terminal fragment of the cucumber mosaic virus (CMV) capsid protein—nCMV, rendering the antigens oligomeric. In a step-by-step manner, RNA was attached as a PAMP, and/or a universal Th-cell epitope was genetically added for additional Th. Finally, a PASP was added to the constructs by displaying the antigens highly organized and repetitively on the surface of CMV-derived virus-like particles (CuMV VLPs). Sera from immunized mice demonstrated that each component contributed stepwise to the immunogenicity of both proteins. All components combined in the CuMV VLP platform induced by far the highest antibody responses. In addition, the DV1 EDIII induced high levels of DENV-1-neutralizing antibodies only if displayed on VLPs. Thus, combining multiple cues typically associated with viruses results in optimal antibody responses.Keywords
Funding Information
- Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (310030_185114, 310030_185114, IZRPZO_194968)
- Delivering a Radical Innovation in Vaccine Development (DRIVE) (310030_185114, 310030_185114, IZRPZO_194968)
- Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (310030_185114, 310030_185114, IZRPZO_194968)
This publication has 275 references indexed in Scilit:
- N‐Terminal Modification of Gly‐His‐Tagged Proteins with AzidogluconolactoneChemBioChem, 2021
- Toward a structural understanding of nucleic acid‐sensing Toll‐like receptors in the innate immune systemFEBS Letters, 2017
- Peptide nanospheres self‐assembled from a modified β‐annulus peptide of Sesbania mosaic virusPeptide Science, 2015
- Vaccine molecules targeting Xcr1 on cross‐presenting DCs induce protective CD8+ T‐cell responses against influenza virusEuropean Journal of Immunology, 2014
- Development and scale‐up of a commercial fed batch refolding process for an anti‐CD22 two chain immunotoxinBiotechnology Progress, 2014
- Titrating T‐Cell Epitopes within Self‐Assembled Vaccines Optimizes CD4+ Helper T Cell and Antibody OutputsAdvanced Healthcare Materials, 2014
- Virus‐like particles induce robust human T‐helper cell responsesEuropean Journal of Immunology, 2011
- Self‐Assembled Synthetic Viral Capsids from a 24‐mer Viral Peptide FragmentAngewandte Chemie International Edition, 2010
- Nucleic acid agonists for Toll‐like receptor 7 are defined by the presence of uridine ribonucleotidesEuropean Journal of Immunology, 2006
- Universally immunogenic T cell epitopes: promiscuous binding to human MHC class II and promiscuous recognition by T cellsEuropean Journal of Immunology, 1989